US20010049396A1 - Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma - Google Patents

Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma Download PDF

Info

Publication number
US20010049396A1
US20010049396A1 US09/367,950 US36795099A US2001049396A1 US 20010049396 A1 US20010049396 A1 US 20010049396A1 US 36795099 A US36795099 A US 36795099A US 2001049396 A1 US2001049396 A1 US 2001049396A1
Authority
US
United States
Prior art keywords
formoterol
asthma
budesonide
active ingredient
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/367,950
Other languages
English (en)
Inventor
Tommy Ekstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20411658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20010049396(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra AB filed Critical Astra AB
Assigned to ASTRA AKTIEBOLAG reassignment ASTRA AKTIEBOLAG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EKSTROM, TOMMY
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB CERTIFICATE OF REGISTRATION Assignors: ASTRA AKTIEBOLAG
Publication of US20010049396A1 publication Critical patent/US20010049396A1/en
Priority to US10/665,240 priority Critical patent/US9295644B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
US09/367,950 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma Abandoned US20010049396A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/665,240 US9295644B2 (en) 1998-06-11 2003-09-19 Methods and compositions for treating asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802073A SE9802073D0 (sv) 1998-06-11 1998-06-11 New use
SE9802073-8 1998-06-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/001031 A-371-Of-International WO1999064014A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/665,240 Continuation US9295644B2 (en) 1998-06-11 2003-09-19 Methods and compositions for treating asthma

Publications (1)

Publication Number Publication Date
US20010049396A1 true US20010049396A1 (en) 2001-12-06

Family

ID=20411658

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/367,950 Abandoned US20010049396A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
US10/665,240 Active 2024-05-20 US9295644B2 (en) 1998-06-11 2003-09-19 Methods and compositions for treating asthma

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/665,240 Active 2024-05-20 US9295644B2 (en) 1998-06-11 2003-09-19 Methods and compositions for treating asthma

Country Status (35)

Country Link
US (2) US20010049396A1 (hu)
EP (3) EP1316311A1 (hu)
JP (1) JP2002517450A (hu)
KR (1) KR20010052721A (hu)
CN (1) CN100389771C (hu)
AR (1) AR018410A1 (hu)
AT (1) ATE389409T1 (hu)
AU (1) AU771715B2 (hu)
BR (1) BR9911073A (hu)
CA (1) CA2334411C (hu)
CY (1) CY1110376T1 (hu)
CZ (1) CZ300874B6 (hu)
DE (1) DE69938390T2 (hu)
DK (1) DK1085877T3 (hu)
EE (1) EE05661B1 (hu)
ES (1) ES2302384T3 (hu)
HK (1) HK1035145A1 (hu)
HU (1) HUP0103108A3 (hu)
ID (1) ID27937A (hu)
IL (2) IL139921A0 (hu)
IS (1) IS5752A (hu)
MY (1) MY129281A (hu)
NO (3) NO20006253L (hu)
NZ (1) NZ536279A (hu)
PL (1) PL344665A1 (hu)
PT (1) PT1085877E (hu)
RU (1) RU2222332C2 (hu)
SA (1) SA99200234B1 (hu)
SE (1) SE9802073D0 (hu)
SK (1) SK286252B6 (hu)
TR (1) TR200003666T2 (hu)
TW (1) TWI252756B (hu)
UA (1) UA87956C2 (hu)
WO (1) WO1999064014A1 (hu)
ZA (1) ZA200006943B (hu)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129245A1 (en) * 2000-05-19 2003-07-10 Eva Trofast Novel process
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070207091A1 (en) * 2006-03-01 2007-09-06 Mcaffer Ian G C Nebulizer Formulation
US10226421B2 (en) 2013-04-10 2019-03-12 Zambon S.P.A. Pharmaceutical composition containing budesonide and formoterol
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
US20210308150A1 (en) * 2010-07-16 2021-10-07 Cipla Limited Pharmaceutical Compositions

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
HU230804B1 (hu) 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
ATE267591T1 (de) 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003037303A1 (en) 2001-11-01 2003-05-08 Nektar Therapeutics Spray drying methods and compositions thereof
FI20020126A0 (fi) * 2002-01-23 2002-01-23 Orion Corp Koostumuksia pulmonaaliseen antoon
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
MX2009008582A (es) 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
MX2009008794A (es) 2007-02-19 2009-08-25 Cipla Ltd Combinaciones farmaceuticas al menos de dos broncodilatadores o de un broncodilatador con un corticosteroide.
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
DK2538922T3 (en) * 2010-02-25 2016-07-04 Andi-Ventis Ltd The formulation of compositions for the treatment of inflammatory conditions
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
US9433576B2 (en) 2010-09-29 2016-09-06 Pulmatrix, Inc. Cationic dry powders
AU2011308865B2 (en) 2010-09-29 2017-01-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
IT202000006442A1 (it) 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
US5674860A (en) * 1991-12-18 1997-10-07 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
US5684199A (en) * 1993-12-28 1997-11-04 Novartis Corporation Process for the preparation of an optically pure enantiomer of formoterol
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5996576A (en) * 1995-09-27 1999-12-07 Glaxo Group Limited Atomising nozzle
US6030604A (en) * 1997-01-20 2000-02-29 Astra Aktiebolag Formulation for inhalation
US6227862B1 (en) * 1999-02-12 2001-05-08 Advanced Drivers Education Products And Training, Inc. Driver training system
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203401A (en) 1979-01-29 1980-05-20 General Motors Corporation Evaporative emissions canister
DK0416950T3 (da) 1989-09-08 1993-10-11 Glaxo Group Ltd Medikamenter
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5119791A (en) 1991-06-07 1992-06-09 General Motors Corporation Vapor storage canister with liquid trap
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP1086697A2 (en) 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
US5408977A (en) 1993-08-23 1995-04-25 Walbro Corporation Fuel tank with carbon canister and shut-off valve
PT721331E (pt) 1993-10-01 2002-05-31 Astrazeneca Ab Processo i
US5511957A (en) 1994-09-27 1996-04-30 Walbro Corporation High capacity fuel pump and filter combination
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
ES2236757T3 (es) 1995-11-24 2005-07-16 Glaxosmithkline S.P.A. Derivados de quinolina.
US5651349A (en) 1995-12-11 1997-07-29 Chrysler Corporation Purge system flow monitor and method
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
BR9810452A (pt) 1997-06-27 2000-09-05 Astra Ab Nova combinação de medicamentos contra asma
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US5957114A (en) 1998-07-17 1999-09-28 Ford Motor Company Evaporative emission canister for an automotive vehicle
US5924410A (en) 1998-07-20 1999-07-20 Ford Motor Company Evaporative emission canister for an automotive vehicle
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
DE60016990T2 (de) 1999-02-26 2005-12-29 Walbro Corp., Cass City Fahrzeugbrennstoffsystem
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
US6237574B1 (en) 1999-04-20 2001-05-29 Ford Motor Company Evaporative emission canister for an automotive vehicle
US6136075A (en) 1999-05-03 2000-10-24 Westvaco Corporation Automotive evaporative emissions canister adsorptive restraint system
JP3646217B2 (ja) 1999-07-08 2005-05-11 愛三工業株式会社 キャニスタモジュール
US6374811B1 (en) 2000-10-04 2002-04-23 Ford Global Technologies, Inc. System and method for minimizing fuel evaporative emissions from an internal combustion engine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5674860A (en) * 1991-12-18 1997-10-07 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
US5972919A (en) * 1991-12-18 1999-10-26 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
US5684199A (en) * 1993-12-28 1997-11-04 Novartis Corporation Process for the preparation of an optically pure enantiomer of formoterol
US5996576A (en) * 1995-09-27 1999-12-07 Glaxo Group Limited Atomising nozzle
US6030604A (en) * 1997-01-20 2000-02-29 Astra Aktiebolag Formulation for inhalation
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6227862B1 (en) * 1999-02-12 2001-05-08 Advanced Drivers Education Products And Training, Inc. Driver training system

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129245A1 (en) * 2000-05-19 2003-07-10 Eva Trofast Novel process
US7179489B2 (en) * 2000-05-19 2007-02-20 Astrazeneca Ab Process for preparing a pharmaceutical composition containing an active ingredient and a micronised carrier/diluent
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070207091A1 (en) * 2006-03-01 2007-09-06 Mcaffer Ian G C Nebulizer Formulation
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
US20210308150A1 (en) * 2010-07-16 2021-10-07 Cipla Limited Pharmaceutical Compositions
US10226421B2 (en) 2013-04-10 2019-03-12 Zambon S.P.A. Pharmaceutical composition containing budesonide and formoterol

Also Published As

Publication number Publication date
NO20130269L (no) 2001-02-12
CZ20004593A3 (cs) 2001-04-11
US20040063676A1 (en) 2004-04-01
HK1035145A1 (en) 2001-11-16
IL139921A0 (en) 2002-02-10
SE9802073D0 (sv) 1998-06-11
MY129281A (en) 2007-03-30
KR20010052721A (ko) 2001-06-25
SK18882000A3 (sk) 2001-07-10
TR200003666T2 (tr) 2001-06-21
AU4671099A (en) 1999-12-30
ATE389409T1 (de) 2008-04-15
TWI252756B (en) 2006-04-11
SK286252B6 (sk) 2008-06-06
IL139921A (en) 2006-10-05
AU771715B2 (en) 2004-04-01
EP2266574A1 (en) 2010-12-29
HUP0103108A2 (hu) 2002-05-29
ES2302384T3 (es) 2008-07-01
CZ300874B6 (cs) 2009-09-02
SA99200234B1 (ar) 2007-03-10
PL344665A1 (en) 2001-11-19
EP1085877B1 (en) 2008-03-19
PT1085877E (pt) 2008-05-13
EE200000740A (et) 2002-04-15
NO20006253D0 (no) 2000-12-08
UA87956C2 (uk) 2009-09-10
CY1110376T1 (el) 2015-04-29
BR9911073A (pt) 2001-02-20
AR018410A1 (es) 2001-11-14
NZ536279A (en) 2007-01-26
CN100389771C (zh) 2008-05-28
US9295644B2 (en) 2016-03-29
EE05661B1 (et) 2013-06-17
DE69938390T2 (de) 2009-03-05
CA2334411A1 (en) 1999-12-16
DE69938390D1 (de) 2008-04-30
ID27937A (id) 2001-05-03
EP1316311A1 (en) 2003-06-04
EP1085877A1 (en) 2001-03-28
HUP0103108A3 (en) 2002-11-28
CA2334411C (en) 2008-07-15
DK1085877T3 (da) 2008-06-09
CN1305380A (zh) 2001-07-25
IS5752A (is) 2000-12-05
JP2002517450A (ja) 2002-06-18
RU2222332C2 (ru) 2004-01-27
NO20140823L (no) 2001-02-12
NO20006253L (no) 2001-02-12
WO1999064014A1 (en) 1999-12-16
ZA200006943B (en) 2002-02-27

Similar Documents

Publication Publication Date Title
EP1085877B1 (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
AU715319B2 (en) New combination
US7897646B2 (en) Use for budesonide and formoterol
JP2014005312A (ja) 喘息の増悪の予防および／または治療のためのフォルモテロールおよびジプロピオン酸ベクロメタゾンを含む組成物の使用
WO1999000134A1 (en) New combination of antiasthma medicaments
MXPA00011806A (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
MXPA98004357A (en) New combination

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTRA AKTIEBOLAG, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EKSTROM, TOMMY;REEL/FRAME:010634/0814

Effective date: 19990615

AS Assignment

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: CERTIFICATE OF REGISTRATION;ASSIGNOR:ASTRA AKTIEBOLAG;REEL/FRAME:011644/0299

Effective date: 20000215

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION